Whalesbook
EPL Limited has issued a corrigendum to its postal ballot notice, originally dated February 23, 2026. The amendment clarifies Item No. 3, providing further details on director appointments and employee stock options (ESOPs) for Mr. Hemant Bakshi, including the 19,23,319 options granted to him. The original notice had also covered the appointments of Mr. Anand Kripalu as Non-Executive, Non-Independent Director and Mr. Hemant Bakshi as Director, Managing Director & Global Chief Executive Officer. This clarification ensures shareholders receive complete and accurate information regarding director appointments and their associated remuneration components, such as ESOPs, enabling informed voting decisions.
Company Background
EPL Limited, formerly Essel Propack, is a leading global producer of laminated tubes for oral care, personal care, and pharmaceuticals, operating over 20 facilities worldwide. It is the largest manufacturer of laminated plastic tubes globally. The company has a history of using postal ballots for significant shareholder approvals, including the recent confirmation of Mr. Aloke Lohia's appointment as Non-Executive, Non-Independent Director. EPL has also been active in allotting shares under its Employee Stock Option Scheme (ESOS) in recent months.
Shareholder Voting Deadline
Shareholders are reminded that remote e-voting for the postal ballot concludes on March 26, 2026. The outcome of this vote will confirm shareholder approval for the director appointments and the clarified ESOP details. EPL continues to utilize remote e-voting as its sole method for shareholder approvals.
Market Context and Peers
EPL Limited holds a leading position in the global laminated tube market, a segment distinct from broader flexible packaging offered by competitors like UFlex Limited and Amcor plc. While other companies such as West Pharmaceutical Services and Huhtamaki India Ltd also operate in pharmaceutical packaging, EPL's specialization in laminated tubes sets its market position apart.
Potential Risks
The company's filing did not detail specific risks related to this corrigendum or the underlying appointments.